Geron Corporation (GERN) Stock

Geron Corporation (GERN) is a Healthcare stock trading at $1.27 (as of 2026-06-18), with a market capitalization of $801.90M and a trailing P/E of -11.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Geron Corporation is a clinical biopharmaceutical company focused on developing and commercializing therapeutics for myeloid hematologic malignancies. Its lead candidate, imetelstat, is a telomerase inhibitor being studied in Phase 3 for myelodysplastic syndromes and myelofibrosis.

Valuation — source: SEC EDGAR (first-party)
Price	$1.27
Market Cap	$801.90M
P/E Ratio	-11.5
EV / EBITDA	-16.8
Price / Book	3.53
Price / Sales	26.63
DCF Value (model)	$-3.02
DCF Upside vs Price	-337.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$18.12M
Net Margin	-460.9%
Return on Equity	-29.4%
Debt / Equity	0.52
Current Ratio	6.78
Revenue Growth (YoY)	-7.6%
EPS Growth (YoY)	-51.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.64 (distress)

Valuation vs Sector & Industry
Stock P/E	-11.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-154.7%
vs Industry	-166.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($95.02M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Harout Semerjian
Employees	229
Country	US
IPO Date	1996-07-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.